The present invention relates to compounds of formula (I) ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3 R.sup.3a and R.sup.3b are as provided in the description, and pharmaceutically acceptable salts thereof, for use in the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors such as obesity.